Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users
- 14 November 2012
- journal article
- Published by Elsevier BV in Contraception
- Vol. 87 (2), 220-226
- https://doi.org/10.1016/j.contraception.2012.10.008
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Predictors of noncompliance in an oral contraceptive clinical trialContraception, 2011
- Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrelContraception, 2011
- Ovarian Suppression in Normal-Weight and Obese Women During Oral Contraceptive UseObstetrics & Gynecology, 2010
- Pharmacokinetics of a combined oral contraceptive in obese and normal-weight womenContraception, 2010
- Contraceptive considerations in obese womenContraception, 2009
- Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activityContraception, 2009
- Obesity and reproduction: an educational bulletinFertility and Sterility, 2008
- Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.2001
- Pharmacokinetics of gestagens: Some problemsAmerican Journal of Obstetrics and Gynecology, 1990
- Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administrationContraception, 1975